NCT04398940 - A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

October 31, 2022

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

TQ-B3139

TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.

Trial Locations (16)

100010

NOT_YET_RECRUITING

The Sixth Medical Center of PLA General Hospital, Beijing

100021

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100053

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing

100071

NOT_YET_RECRUITING

The Fifth Medical Center of PLA General Hospital, Beijing

100142

NOT_YET_RECRUITING

Beijing Cancer Hospital, Beijing

150000

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

200032

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

210009

NOT_YET_RECRUITING

Jiangsu Cancer Hospital, Nanjing

230000

NOT_YET_RECRUITING

Anhui Provincial Hospital, Hefei

300041

NOT_YET_RECRUITING

Tianjin Medical University General Hospital, Tianjin

310016

NOT_YET_RECRUITING

Sir Run Shaw Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

310022

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

410013

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

450008

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

530021

NOT_YET_RECRUITING

Guangxi Medical University Affiliated Tumor Hospital, Nanning